Duo Shared Genomic Segment analysis identifies a genome-wide significant risk locus at 18q21.33 in myeloma pedigrees

Abstract

Aim: High-risk pedigrees (HRPs) are a powerful design to map highly penetrant risk genes. We previously described Shared Genomic Segment (SGS) analysis, a mapping method for single large extended pedigrees that also addresses genetic heterogeneity inherent in complex diseases. SGS identifies shared segregating chromosomal regions that may inherit in only a subset of cases. However, single large pedigrees that are individually powerful (at least 15 meioses between studied cases) are scarce. Here, we expand the SGS strategy to incorporate evidence from two extended HRPs by identifying the same segregating risk locus in both pedigrees and allowing for some relaxation in the size of each HRP.

Methods: Duo-SGS is a procedure to combine single-pedigree SGS evidence. It implements statistically rigorous duo-pedigree thresholding to determine genome-wide significance levels that account for optimization across pedigree pairs. Single-pedigree SGS identifies optimal segments shared by case subsets at each locus across the genome, with nominal significance assessed empirically. Duo-SGS combines the statistical evidence for SGS segments at the same genomic location in two pedigrees using Fisher’s method. One pedigree is paired with all others and the best duo-SGS evidence at each locus across the genome is established. Genome-wide significance thresholds are determined through distribution-fitting and the Theory of Large Deviations. We applied the duo-SGS strategy to eleven extended, myeloma HRPs.

Results: We identified one genome-wide significant region at 18q21.33 (0.85 Mb, P = 7.3 × 10^-9) which contains one gene, CDH20. Thirteen regions were genome-wide suggestive: 1q42.2, 2p16.1, 3p25.2, 5q21.3, 5q31.1, 6q16.1, 6q26, 7q11.23, 12q24.31, 13q13.3, 18p11.22, 18q22.3 and 19p13.12.

Conclusion: Our results provide novel risk loci with segregating evidence from multiple HRPs and offer compelling targets and specific segment carriers to focus a future search for functional variants involved in inherited risk formyeloma.

Keywords

High-risk pedigrees / gene mapping / multiple myeloma / disease susceptibility

References

[1] SungH,SiegelRL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries..CA Cancer J Clin2021;

[2] MorganGJ,WeinholdN.Inherited genetic susceptibility to multiple myeloma..Leukemia2014;28:518-24

[3] GrosboisB,AttalM.Familial multiple myeloma: report of fifteen families..Br J Haematol1999;105:768-70

[4] HemminkiK,CzeneK.Familial risk of cancer: data for clinical counseling and cancer genetics..Int J Cancer2004;108:109-14

[5] VanValkenburgME,BrillIK.Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features..Cancer Causes Control2016;27:81-91 PMCID:PMC4703620

[6] BourguetCC,DelzellE,CohenHJ.Multiple myeloma and family history of cancer a case-control study..Cancer1985;56:2133-9

[7] ErikssonM.Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study..Cancer Causes Control1992;3:63-7

[8] SchinasiLH,CampNJ.Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium..Br J Haematol2016;175:87-101 PMCID:PMC5035512

[9] LandgrenO,McMasterML,HemminkiK.Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study..Int J Cancer2006;118:3095-8

[10] KristinssonSY,GoldinLR.Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden..Int J Cancer2009;125:2147-50 PMCID:PMC2737604

[11] AltieriA,BermejoJL,HemminkiK.Familial risks and temporal incidence trends of multiple myeloma..Eur J Cancer2006;42:1661-70

[12] SudA,HoulstonRS.Genome-wide association studies of cancer: current insights and future perspectives..Nat Rev Cancer2017;17:692-704

[13] MitchellJS,WeinholdN.Genome-wide association study identifies multiple susceptibility loci for multiple myeloma..Nat Commun2016;7:12050 PMCID:PMC4932178

[14] WeinholdN,ChubbD.The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma..Nat Genet2013;45:522-5 PMCID:PMC5056630

[15] WentM,FörstiA.Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma..Nat Commun2018;9:3707 PMCID:PMC6137048

[16] SwaminathanB,JöudM.Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma..Nat Commun2015;6:7213 PMCID:PMC4455110

[17] ChubbD,BroderickP.Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk..Nat Genet2013;45:1221-5 PMCID:PMC5053356

[18] BroderickP,JohnsonDC.Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk..Nat Genet2011;44:58-61 PMCID:PMC5108406

[19] HalvarssonBM,AliM.Direct evidence for a polygenic etiology in familial multiple myeloma..Blood Adv2017;1:619-23 PMCID:PMC5728350

[20] WallerRG,WeiX.Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk..PLoS Genet2018;14:e1007111 PMCID:PMC5794067

[21] WeiX,ChenS.Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma..Cancer Res2018;78:2747-59 PMCID:PMC5955848

[22] PertesiM,WeiX.Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma..Leukemia2019;33:2324-30 PMCID:PMC6756025

[23] ThomasA,FarnhamJM,Cannon-AlbrightLA.Shared genomic segment analysis. Mapping disease predisposition genes in extended pedigrees using SNP genotype assays..Ann Hum Genet2008;72:279-87 PMCID:PMC2964273

[24] KnightS,AbelHJ.Shared genomic segment analysis: the power to find rare disease variants..Ann Hum Genet2012;76:500-9 PMCID:PMC3879794

[25] McClellanJ.Genetic heterogeneity in human disease..Cell2010;141:210-7

[26] LanderE.Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results..Nat Genet1995;11:241-7

[27] HansonHA,MadsenMJ.Family Study Designs Informed by Tumor Heterogeneity and Multi-Cancer Pleiotropies: The Power of the Utah Population Database..Cancer Epidemiol Biomarkers Prev2020;29:807-15 PMCID:PMC7168701

[28] PurcellS,Todd-BrownK.PLINK: a tool set for whole-genome association and population-based linkage analyses..Am J Hum Genet2007;81:559-75 PMCID:PMC1950838

[29] JeanesA,YapAS.Cadherins and cancer: how does cadherin dysfunction promote tumor progression?.Oncogene2008;27:6920-9 PMCID:PMC2745643

[30] XuL,YinD.An emerging role of PARK2 in cancer..J Mol Med (Berl)2014;92:31-42

[31] XiongD,KupertE.A recurrent mutation in PARK2 is associated with familial lung cancer..Am J Hum Genet2015;96:301-8 PMCID:PMC4320264